Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 2
2002 2
2003 2
2004 2
2005 1
2007 5
2008 8
2009 4
2010 8
2011 8
2012 14
2013 18
2014 12
2015 11
2016 11
2017 15
2018 27
2019 19
2020 25
2021 30
2022 55
2023 50
2024 51
2025 44

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

361 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Blauvelt A, et al. Among authors: prajapati vh. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. JAMA Dermatol. 2021. PMID: 34347860 Free PMC article. Clinical Trial.
Expert consensus on the systemic treatment of atopic dermatitis in special populations.
Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, Lansang P, Lynde CW, Papp KA, Prajapati VH, Turchin I, Yeung J. Adam DN, et al. Among authors: prajapati vh. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1135-1148. doi: 10.1111/jdv.18922. Epub 2023 Feb 8. J Eur Acad Dermatol Venereol. 2023. PMID: 36695072 Review.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, Hu X, Wu T, Calimlim BM, Kaplan B, Liu Y, Teixeira HD, Liu J, Eyerich K. Blauvelt A, et al. Among authors: prajapati vh. J Am Acad Dermatol. 2023 Sep;89(3):478-485. doi: 10.1016/j.jaad.2023.05.033. Epub 2023 May 23. J Am Acad Dermatol. 2023. PMID: 37230366 Free article. Clinical Trial.
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, Gooderham M, Gonzalez ME, Hebert AA, Kircik LH, Lomaga M, Moore A, Papp KA, Prajapati VH, Hanna D, Snyder S, Krupa D, Burnett P, Almaraz E, Higham RC, Chu DH, Berk DR. Simpson EL, et al. Among authors: prajapati vh. JAMA Dermatol. 2024 Nov 1;160(11):1161-1170. doi: 10.1001/jamadermatol.2024.3121. JAMA Dermatol. 2024. PMID: 39292443 Free PMC article. Clinical Trial.
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Paller AS, et al. Among authors: prajapati vh. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. JAMA Dermatol. 2023. PMID: 37043227 Free PMC article. Clinical Trial.
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, Prajapati VH, Sapra S, Brzewski P, Osman L, Hanna S, Wiseman MC, Hamilton C, Cassella J. King B, et al. Among authors: prajapati vh. J Am Acad Dermatol. 2024 Nov;91(5):880-888. doi: 10.1016/j.jaad.2024.06.097. Epub 2024 Jul 23. J Am Acad Dermatol. 2024. PMID: 39053611 Free article. Clinical Trial.
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Mendes-Bastos P, et al. Among authors: prajapati vh. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. J Am Acad Dermatol. 2022. PMID: 35714786 Free article. Clinical Trial.
Proteostasis in neurodegenerative diseases.
Kinger S, Jagtap YA, Kumar P, Choudhary A, Prasad A, Prajapati VK, Kumar A, Mehta G, Mishra A. Kinger S, et al. Among authors: prajapati vk. Adv Clin Chem. 2024;121:270-333. doi: 10.1016/bs.acc.2024.04.002. Epub 2024 Apr 30. Adv Clin Chem. 2024. PMID: 38797543 Review.
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.
Sood S, Rimke A, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Stark LA, Devani AR, Vender R, Yeung J, Prajapati VH. Sood S, et al. Among authors: prajapati vh. J Am Acad Dermatol. 2024 Nov;91(5):936-939. doi: 10.1016/j.jaad.2024.05.085. Epub 2024 Jun 15. J Am Acad Dermatol. 2024. PMID: 38885841 No abstract available.
Interleukin-17-A multifaceted cytokine in viral infections.
Sahu U, Biswas D, Prajapati VK, Singh AK, Samant M, Khare P. Sahu U, et al. Among authors: prajapati vk. J Cell Physiol. 2021 Dec;236(12):8000-8019. doi: 10.1002/jcp.30471. Epub 2021 Jun 16. J Cell Physiol. 2021. PMID: 34133758 Free PMC article. Review.
361 results